![]() (click to download) |
Clearing the fog: Patenting trends for the treatment of Alzheimer's disease. The white paper has applied Network Patent Analysis™ (NPA™) to 48,000 patents in the area of Alzheimer's treatments to show the leading patents, patenting areas, patent owners and inventors. But which treatments are receiving the most investment? Ambercite teamed up with its partner Griffith Hack to create this white paper that should be of natural interest to those working in the life sciences area or with a general interest in Alzheimer’s disease, and also to those interested in the advanced ability of NPA to filter, group and rank patents in any area of technology. The paper is accompanied by two NPA patent landscape maps showing highlighting the leading clusters and patent filing trends in this increasingly important area. |
Ambercite and its products including Network Patent Analysis (NPA) and AmberScope analyse patent data using a statistical based approach that is based on available patent citation and ownership data. These outputs are purely mathematical in nature, and do not take into account the personal or professional opinions of any individuals or associates of Ambercite. These outputs are intended to be used as tool to help support further analysis, and should not be used by itself and without professional advice on the relevancy of this data to your unique circumstances. Data should not be relied upon to prove without any further analysis any opinion of the value, patentability, validity, freedom to operate or infringement of any patent, patents or inventions. Users should also be aware that available patent citation data is imperfect, and this will affect the results of this analysis. © Patent Analytics Holding Pty Ltd. Ambercite™, Network Patent Analysis™, NPA™ and Next Generation Patent mapping™ are trade marks of Patent Analytics Holding Pty Ltd. Components of the processes used to perform Network Patent Analysis and AmberScope are the subject of patent applications filed in the United States and elsewhere.